Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Oncopeptides AB
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, between the ages of 18 years and 70 years at the planned time of study treatment; patients greater than 70 years of age may qualify on a case by case basis
Diagnosis of multiple myeloma
Received a previous Autologous Stem Cell Transplantation ( ASCT) (single or tandem) that resulted in disease progression within 24 months
Received at least 2 prior lines of therapy
Refractory to previous treatment with a Proteasome Inhibitor (PI), an immunomodulatory drug (IMiD) and an anti-Cluster of Differentiation 38 monoclonal antibody (anti-CD38 mAb)
Male and women of childbearing potential agrees to use contraception during the treatment period and during a specified time period after the last dose
You may not be if
Prior treatment with melphalan flufenamide (melflufen) or OPD5
Any medical condition that may interfere with safety or participation in this study
Other malignancy diagnosed or requiring treatment within the past 3 years with the exception of adequately treated basal cell carcinoma, squamous cell skin cancer, carcinoma in-situ of the cervix or breast or very low and low risk prostate cancer in active surveillance
Prior allogeneic stem cell transplantation or prior salvage ASCT
